尼妥珠单抗的放疗增敏研究现状及进展  

Present situation and advances on the nimotuzumab related radiosensitivity research

作　　者：滕凯[1,2] 张用[1] 刘莉[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院肿瘤中心,武汉430022 [2]海南省肿瘤医院

出　　处：《实用肿瘤学杂志》2015年第3期245-249,共5页Practical Oncology Journal

基　　金：中国抗癌协会培育基金

摘　　要：大量研究表明，EGFR信号通路与放疗抵抗相关，许多恶性肿瘤高度表达EGFR。 EGFR阻断成为放疗增敏的途径之一。作为第一个由中国和古巴合作研制的EGFR单克隆抗体，尼妥珠单抗有其独特的临床特性，其联合放疗在头颈部肿瘤、食管癌和高级别脑胶质瘤等肿瘤中得到了广泛的研究及探索，本文就尼妥珠单抗放疗增敏的研究现状及进展做一综述。With data support from abundant research ,epithelial growth factor receptor （ EGFR） signaling pathway is associated with radiotherapy resistance .EGFR inhibition has become one of methods to increase radio-sensitivity.As the first EGFR monoclonal antibody developed by China and Cuba ,nimotuzumab demonstrates its distinct clinical characteristics and has been extensively explored in head and neck cancer , esophageal cancer , high grade glioma .This article mainly reviews the present situation and recent advances on the radiosensitivity re -search of nimotuzumab .

关 键 词：尼妥珠单抗 放射敏感性 肿瘤 

分 类 号：R730.55[医药卫生—肿瘤]